Next Article in Journal / Special Issue
Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2
Previous Article in Journal
3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2016, 9(1), 3; doi:10.3390/ph9010003

The Role of Immunotherapy in Multiple Myeloma

Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD 21201, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editors: Ashkan Emadi and Dhimant Desai
Received: 11 November 2015 / Revised: 29 December 2015 / Accepted: 6 January 2016 / Published: 14 January 2016
(This article belongs to the Special Issue Chemotherapeutic Agents)
View Full-Text   |   Download PDF [389 KB, uploaded 14 January 2016]   |  

Abstract

Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many of these treatments are under clinical development and have already started providing encouraging results. We, for the second time in the last two decades, are about to witness another shift of the paradigm in the management of this ailment. This review will summarize the major approaches in myeloma immunotherapies. View Full-Text
Keywords: myeloma; immunotherapy; vaccines; tumor antigens; antibodies; CAR-T; adoptive cell therapy myeloma; immunotherapy; vaccines; tumor antigens; antibodies; CAR-T; adoptive cell therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kocoglu, M.; Badros, A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals 2016, 9, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top